Q&M completes Ann Arbor; Aoxin's old shortfall is gone
SGX:QC7 — Ann Arbor (S$1.2M, Singapore) completed 10 June; Aoxin subsidiaries met all FY2025 profit guarantees; legacy RMB 2.68M shortfall fully repaid. Thesis intact.
Two announcements landed on Q&M in the past week that deserve a quick read-through together, not because either is large on its own, but because they move the same variable: confidence that the execution machinery actually works.
The first is the completion of the Ann Arbor Dental Surgery acquisition, announced on 10 June. The second, from 5 June, is the FY2025 profit guarantee results for Aoxin Q&M’s three legacy northern China subsidiaries: all met, and the last outstanding shortfall from the pre-FY2023 period has been repaid in full.
A quick note on scope: Ann Arbor did not appear in our initiation article. It is one of three small Singapore bolt-on acquisitions (alongside Sengkang Dental Surgery, completed January 2026, and Southbank Private Limited / TEETH @ Tiong Bahru, binding MOU February 2026) that Q&M has been running in parallel with the headline international deals. Each is too small individually to feature in an S$130M thesis, and none changes the international expansion story. But together they confirm that the Singapore accretion engine, the model that built Q&M from one clinic to 110+ over thirty years, is still running while management pursues the larger bets.
Neither event is material in isolation. Together they clear two items that were sitting open on the bear checklist.